<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150591</url>
  </required_header>
  <id_info>
    <org_study_id>F32HL097383</org_study_id>
    <nct_id>NCT01150591</nct_id>
  </id_info>
  <brief_title>Microaspiration in Pulmonary Fibrosis</brief_title>
  <acronym>ROMI</acronym>
  <official_title>The Role of Microaspiration in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1: Microaspiration, as diagnosed by bronchoalveolar lavage (BAL) pepsin, is common&#xD;
      in patients with IPF.&#xD;
&#xD;
      Hypothesis 2a: Baseline clinical variables and co-morbid conditions are risk factors for&#xD;
      microaspiration in patients with IPF.&#xD;
&#xD;
      Hypothesis 2b: Baseline biological variables reflecting alveolar epithelial injury and&#xD;
      inflammation are markers of microaspiration in IPF.&#xD;
&#xD;
      Hypothesis 3a: Microaspiration will lead to a more rapid rate of decline in pulmonary&#xD;
      function.&#xD;
&#xD;
      Hypothesis 3b: Microaspiration will lead to higher rates of urgent medical care use (i.e.&#xD;
      unscheduled clinic visit, emergency room visit, or hospitalization).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BAL pepsin level</measure>
    <time_frame>Cross sectional</time_frame>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <biospec_descr>
    <textblock>
      This is a prospective cohort study of patients with IPF. Subjects will undergo (1) an&#xD;
      assessment of the presence or absence of microaspiration (via bronchoscopy and BAL pepsin&#xD;
      level), (2) measurement of biomarkers of microaspiration (via esophageal function studies,&#xD;
      laboratory tests, pulmonary function, chest imaging, and survey), and (3) longitudinal&#xD;
      follow-up to document disease progression (via pulmonary function and survey).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with IPF&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of IPF&#xD;
&#xD;
          -  Ability ot provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of fundoplication or other gastroesophageal surgery&#xD;
&#xD;
          -  Too ill to undergo bronchoscopy in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

